Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month High – Here’s Why

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares hit a new 52-week high during trading on Monday . The stock traded as high as $24.49 and last traded at $23.88, with a volume of 70774 shares. The stock had previously closed at $23.23.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. The Goldman Sachs Group upped their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. HC Wainwright increased their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley raised their price target on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.27.

Bicara Therapeutics Trading Up 3.1%

The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -8.61 and a beta of -0.54. The business has a 50-day moving average price of $21.82 and a two-hundred day moving average price of $19.08.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts predict that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Insider Activity

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the sale, the chief executive officer owned 362,152 shares in the company, valued at approximately $8,550,408.72. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,264,943.68. This trade represents a 9.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 63,900 shares of company stock worth $1,420,704. 13.80% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. boosted its position in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $44,484,000. Vestal Point Capital LP lifted its holdings in Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the period. Franklin Resources Inc. acquired a new stake in Bicara Therapeutics in the fourth quarter worth about $27,265,000. Finally, State Street Corp grew its position in Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.